nder mounting pressure over its pricing for a newly approved for a Duchenne muscular dystrophy drug, Marathon Pharmaceuticals made a surprise move on Thursday and agreed to sell the medicine to PTC Therapeutics, which has been battling US regulators over its own treatment for the disease.

The deal, which will give Marathon $140 million initially and additional milestone payments, comes just one month after Marathon won Food and Drug Administration approval to sell a decades-old steroid and slapped an $89,000 price tag on the drug. PTC, meanwhile, did not say what it will now charge.

This is a STAT Plus article and is only available to STAT Plus subscribers.
To read the full story, subscribe to STAT Plus or log in to your account.
Good news: your first 30 days are on us.

Sign up for Morning Rounds

A daily dose of health and medicine news — and a finalist for Digiday’s best email newsletter.

Recommended Stories